Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California. Show more

2200 Bridge Pkwy, Redwood City, CA, 94065, United States

Biotechnology

Healthcare

Market Cap

19.26M

52 Wk Range

$0.69 - $7.19

Previous Close

$0.80

Open

$0.79

Volume

891,070

Day Range

$0.69 - $0.81

Enterprise Value

-5.023M

Cash

28.69M

Avg Qtr Burn

-21.87M

Insider Ownership

1.04%

Institutional Own.

73.20%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Briquilimab (SC) Details Chronic spontaneous urticaria (CSU)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SC) Details Cold urticaria (ColdU) or symptomatic dermographism (SD)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SA SC) Details Asthma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab Details Severe combined immunodeficiency due to complete RAG1/2 deficiency	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.